At a glance
- Originator Unknown
- Developer Novartis
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 25 Nov 1997 Phase-I clinical trials for Solid tumours in Switzerland (Unknown route)
- 25 Nov 1997 Phase-I clinical trials for Solid tumours in USA (Unknown route)
- 25 Nov 1997 Preclinical development for Solid tumours in Japan (Unknown route)